<DOC>
	<DOCNO>NCT00360178</DOCNO>
	<brief_summary>Recruiting Germany : This study evaluate safety efficacy valsartan plus HCTZ fix dose combination hypertensive patient respond treatment free combination Candesartan plus HCTZ . In optional extension patient uncontrolled BP end core study treat valsartan plus HCTZ fix dose combination plus amlodipine 5 mg additional 4 week .</brief_summary>
	<brief_title>Efficacy Safety Valsartan Plus Hydrochlorothiazide Fixed Dose Combination Hypertensive Patients Not Controlled Free Combination Angiotensin Receptor Blocker Plus Hydrochlorothiazide</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Male female patient ( &gt; =18 year ) 2 . Females must either postmenopausal one year , surgically sterile use effective contraceptive method ( e.g . intrauterine device , hormonal contraceptive ) . 3 . Patients moderate essential hypertension ( WHO ) : 1 . Severe hypertension ( WHO ) 2 . Pregnant nursing woman 3 . Treated hypertensive patient control hypertension current therapy ( MSDBP &lt; 90 mmHg MSSBP &lt; 140 mmHg ) 4 . A history cardiovascular disease , include angina pectoris , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , transient ischemic attack , stroke , heart failure NYHA II IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
	<keyword>amlodipine</keyword>
	<keyword>hydrochlorothiazide</keyword>
</DOC>